Literature DB >> 2570456

Drug interactions with quinolones.

B I Davies1, F P Maesen.   

Abstract

Numerous drug interactions with the new 4-quinolone antimicrobial agents have now been established. Many, but not all, quinolones are extensively metabolized and can have inhibitory effects on the liver cytochrome P450 enzyme system, leading to reduced metabolism and clearance of certain other drugs that are normally thus eliminated. Examples include the highly significant interaction between enoxacin and theophylline and the interaction between ciprofloxacin and theophylline, which may also be important clinically. The quinolone-caffeine interaction does not usually cause problems. Absorption of all quinolones from the stomach and small intestine is greatly reduced by antacids containing magnesium or aluminium salts, including sucralfate, probably as a result of the formation of nonabsorbable chelates. Cimetidine can reduce the clearance of pefloxacin (but not of ciprofloxacin) through its effects on liver metabolism, although newer H2-inhibitors appear not to have these effects. Probenecid reduces the renal elimination of some quinolones by inhibiting tubular secretion. New evidence is now coming to light of interactions between certain nonsteroid antiinflammatory drugs (e.g., fenbufen), quinolones, and gamma-aminobutyric acid (GABA) receptors, producing increased cerebral excitation and, sometimes, epileptiform convulsions.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2570456     DOI: 10.1093/clinids/11.supplement_5.s1083

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  22 in total

1.  Effects of iron supplements on the oral bioavailability of moxifloxacin, a novel 8-methoxyfluoroquinolone, in humans.

Authors:  H Stass; D Kubitza
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

2.  Effects of sucralfate on the oral bioavailability of moxifloxacin, a novel 8-methoxyfluoroquinolone, in healthy volunteers.

Authors:  H Stass; U Schühly; J G Möller; H Delesen
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

Review 3.  Pharmacokinetics of antimicrobial agents in organ function impairment. A review.

Authors:  R Janknegt
Journal:  Pharm Weekbl Sci       Date:  1990-08-24

Review 4.  Clinically significant interactions with drugs used in the treatment of tuberculosis.

Authors:  W W Yew
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

5.  Clinical and chemical interactions between iron preparations and ciprofloxacin.

Authors:  M Kara; B B Hasinoff; D W McKay; N R Campbell
Journal:  Br J Clin Pharmacol       Date:  1991-03       Impact factor: 4.335

6.  Proceedings of the British Pharmacological Society. Clinical Pharmacology Section. 14-16 April 1993. Abstracts.

Authors: 
Journal:  Br J Clin Pharmacol       Date:  1993-08       Impact factor: 4.335

7.  Effect of an antacid containing magnesium and aluminum on absorption, metabolism, and mechanism of renal elimination of pefloxacin in humans.

Authors:  U Jaehde; F Sörgel; U Stephan; W Schunack
Journal:  Antimicrob Agents Chemother       Date:  1994-05       Impact factor: 5.191

8.  Antimicrobial drugs encapsulated in fibrin nanoparticles for treating microbial infested wounds.

Authors:  B Maria Alphonsa; P T Sudheesh Kumar; G Praveen; Raja Biswas; K P Chennazhi; R Jayakumar
Journal:  Pharm Res       Date:  2013-11-28       Impact factor: 4.200

Review 9.  Use of the quinolones in paediatrics.

Authors:  U B Schaad
Journal:  Drugs       Date:  1993       Impact factor: 9.546

Review 10.  Ofloxacin. A reappraisal of its use in the management of genitourinary tract infections.

Authors:  S V Onrust; H M Lamb; J A Balfour
Journal:  Drugs       Date:  1998-11       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.